

Terri S Armstrong

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3551381/terri-s-armstrong-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

190
papers

8,288
citations

48
h-index

88
g-index

205
ext. papers

10,175
ext. citations

4.2
avg, IF

5.89
L-index

#	Paper	IF	Citations
190	A randomized trial of bevacizumab for newly diagnosed glioblastoma. <i>New England Journal of Medicine</i> , 2014 , 370, 699-708	59.2	1775
189	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. <i>Cancer Cell</i> , 2015 , 27, 728-43	24.3	672
188	Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4085-91	2.2	623
187	IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. <i>Acta Neuropathologica</i> , 2015 , 129, 585-96	14.3	211
186	Symptoms experience: a concept analysis. <i>Oncology Nursing Forum</i> , 2003 , 30, 601-6	1.7	165
185	A prognostic gene expression signature in infratentorial ependymoma. <i>Acta Neuropathologica</i> , 2012 , 123, 727-38	14.3	131
184	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2468-77	2.2	113
183	Biology and management of ependymomas. <i>Neuro-Oncology</i> , 2016 , 18, 902-13	1	99
182	Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4076-84	2.2	98
181	Chemotherapy-induced peripheral neuropathy. <i>Oncology Nursing Forum</i> , 2005 , 32, 305-11	1.7	90
180	Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2467-74	2.2	87
179	Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. <i>Neuro-Oncology</i> , 2015 , 17, 440-7	1	83
178	Symptom clusters in oncology patients and implications for symptom research in people with primary brain tumors. <i>Journal of Nursing Scholarship</i> , 2004 , 36, 197-206	3.6	82
177	Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience. <i>Neuro-Oncology</i> , 2010 , 12, 862-70	1	79
176	QOLP-14. PRELIMINARY EXAMINATION OF CONFIRMED GLIOMA RISK FACTORS AMONG EPENDYMOMA PATIENTS IN THE NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS) AND RISK AND OUTCOMES STUDY (ROS). <i>Neuro-Oncology</i> , 2018 , 20, vi217-vi217	1	78
175	QOLP-28. THE USE OF VIRTUAL REALITY FOR SYMPTOM MANAGEMENT: APPLICATION IN NEURO-ONCOLOGY. <i>Neuro-Oncology</i> , 2019 , 21, vi203-vi204	1	78
174	NIMG-03. PROSPECTIVE PHASE II RANDOMIZED TRIAL COMPARING PROTON THERAPY VS. PHOTON IMRT FOR GBM: SECONDARY ANALYSIS COMPARISON OF PROGRESSION FREE SURVIVAL BETWEEN RANO VS. CLINICAL AND RADIOLOGICAL ASSESSMENT. <i>Neuro-Oncology</i> , 2019 , 21, vi161-vi162	1	78

173	QOLP-31. ASSESSING THE IMPACT OF GLIOBLASTOMA ON WORK PRODUCTIVITY IN PATIENTS AND THEIR CAREGIVERS. <i>Neuro-Oncology</i> , 2019 , 21, vi204-vi204	1	78
172	HOUT-01. ALOPECIA SYMPTOM IMPACT SCALE (ASIS): MEASURING THE SYMPTOMS OF ALOPECIA AND THEIR IMPACT IN PATIENTS WITH PRIMARY BRAIN TUMORS. <i>Neuro-Oncology</i> , 2019 , 21, vi111-vi112 ¹		78
171	HOUT-22. EVALUATING CLINICAL IMPACT UTILIZING THE RANO-PRO COLLABORATIVE'S STANDARDIZED PRIORITY CONSTRUCTS. <i>Neuro-Oncology</i> , 2019 , 21, vi116-vi117	1	78
170	NIMG-32. CHALLENGES OF IMAGING INTERPRETATION TO PREDICT OLIGODENDROGLIOMA GRADE. <i>Neuro-Oncology</i> , 2019 , 21, vi168-vi168	1	78
169	QOLP-16. CAPTURING THE PRIMARY BRAIN TUMOR (PBT) PATIENT'S EXPERIENCE OF BODY IMAGE DISSATISFACTION: REPORT FROM THE NEURO-ONCOLOGY BRANCH-NATURAL HISTORY STUDY (NOB-NHS). <i>Neuro-Oncology</i> , 2018 , 20, vi217-vi218	1	78
168	RARE-21. A DESCRIPTIVE REPORT OF PATIENTS WITH RARE CENTRAL NERVOUS SYSTEM (CNS) CANCERS ON AN NCI-CONNECT CANCER MOONSHOT IMMUNE CHECKPOINT INHIBITOR TRIAL. <i>Neuro-Oncology</i> , 2018 , 20, vi240-vi240	1	78
167	INNV-43. NUCLEIC ACID ADEQUACY FROM ARCHIVED FORMALIN-FIXED PARAFFIN EMBEDDED (FFPE) TUMOR TISSUE FOR NEXT-GENERATION SEQUENCING (NGS) IN NATIONAL CANCER INSTITUTE (NCI)- NATURAL HISTORY STUDY (NHS) OF PRIMARY CNS TUMOR. <i>Neuro-Oncology</i> , 2018	1	78
166	HOUT-12. CHARACTERIZATION OF SYMPTOM BURDEN IN MINORITY PATIENTS WITH CNS TUMORS: A REPORT FROM THE NEURO-ONCOLOGY BRANCH (NOB) NATURAL HISTORY STUDY (NHS). <i>Neuro-Oncology</i> , 2018 , 20, vi115-vi115	1	78
165	INNV-38. THE NEURO-ONCOLOGY BRANCH TRANSLATIONAL RESEARCH IMMERSION PROGRAM: RESULTS FROM TWO YEARS OF DEVELOPMENT AND PARTICIPANT FEEDBACK. <i>Neuro-Oncology</i> , 2018 , 20, vi145-vi146	1	78
164	QOLP-06. BODY IMAGE DISTURBANCE IN PATIENTS WITH PRIMARY BRAIN TUMORS. <i>Neuro-Oncology</i> , 2018 , 20, vi215-vi215	1	78
163	EXTH-61. PARTNERSHIP FOR DEFINING THE IMPACT OF 12 SELECT RARE CNS TUMORS: A REPORT FROM CBTRUS AND THE NCI-CONNECT. <i>Neuro-Oncology</i> , 2018 , 20, vi98-vi98	1	78
162	HOUT-03. SCREENING FOR MOOD DISTURBANCE IN LONG-TERM CENTRAL NERVOUS SYSTEM (CNS) TUMOR SURVIVORS USING PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS): A NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS) REPORT. <i>Neuro-Oncology</i> , 2018 , 20, vi113-vi113	1	78
161	IMMU-68. SINGLE-CELL PROTEOMIC ANALYSIS OF IMMUNE CELL RESPONSE TO CHECKPOINT BLOCKADE USING 30-PARAMETER FLOW CYTOMETRY. <i>Neuro-Oncology</i> , 2018 , 20, vi137-vi137	1	78
160	QOLP-09. ASSOCIATION BETWEEN BODY IMAGE INVESTMENT AND ALTERATION IN PATIENTS WITH PRIMARY BRAIN TUMORS. <i>Neuro-Oncology</i> , 2018 , 20, vi216-vi216	1	78
159	RARE-26. MUTATIONS IN MAPK PATHWAY GENES ARE CHARACTERISTIC AND CONFIRMATORY OF MULTINODULAR AND VACUOLATING NEURONAL TUMOR OF THE CEREBRUM. <i>Neuro-Oncology</i> , 2018 , 20, vi241-vi241	1	78
158	INNV-33. IMPLEMENTATION OF ELECTRONIC DATA CAPTURE FOR USE IN NATURAL HISTORY STUDIES: UTILITY OF CENTER FOR CANCER RESEARCH'S (CCR) LABMATRIX AND SCRIBE SYSTEMS FOR THE NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS). <i>Neuro-Oncology</i> , 2018 , 20, vi117-vi117	1	78
157	QOLP-26. PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS) SCREENING FOR ANXIETY & DEPRESSION IN CENTRAL NERVOUS SYSTEM(CNS) CANCER: LARGE COHORT REPORT FROM THE NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS).. <i>Neuro-Oncology</i> , 2018 , 20, vi220-vi220	1	78
156	RDNA-13. VALIDATION OF BEHAVIORAL ANALYSIS ACROSS AGE IN A MOUSE MODEL FOR FUTURE INVESTIGATION OF RADIATION-INDUCED HYPERSOMNOLENCE (RIH) IN PRIMARY BRAIN TUMOR (PBT) PATIENTS. <i>Neuro-Oncology</i> , 2018 , 20, vi224-vi224	1	78

155	Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2017 , 35, 361-369	2.2	76
154	A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. <i>Clinical Cancer Research</i> , 2019 , 25, 5799-5807	12.9	72
153	The symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptoms. <i>Neuro-Oncology</i> , 2016 , 18, 252-60	1	67
152	Antiepileptic drugs for preventing seizures in people with brain tumors. <i>The Cochrane Library</i> , 2008 , CD004424	67	
151	Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy. <i>Neuro-Oncology</i> , 2016 , 18, 779-89	1	66
150	Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. <i>Neuro-Oncology</i> , 2017 , 19, 12-21	1	65
149	Pregnancy and glial brain tumors. <i>Neuro-Oncology</i> , 2014 , 16, 1289-94	1	56
148	Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. <i>Neuro-Oncology</i> , 2009 , 11, 825-32	1	55
147	Predictors of survival among pediatric and adult ependymoma cases: a study using Surveillance, Epidemiology, and End Results data from 1973 to 2007. <i>Neuroepidemiology</i> , 2012 , 39, 116-24	5.4	54
146	Practical strategies for management of fatigue and sleep disorders in people with brain tumors. <i>Neuro-Oncology</i> , 2012 , 14 Suppl 4, iv65-72	1	53
145	Risk factors for fatigue severity in primary brain tumor patients. <i>Cancer</i> , 2010 , 116, 2707-15	6.4	53
144	Heterogeneity within the PF-EPN-B ependymoma subgroup. <i>Acta Neuropathologica</i> , 2018 , 136, 227-237	14.3	52
143	Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. <i>Annals of Surgical Oncology</i> , 2009 , 16, 2181-7	3.1	50
142	Content validity of self-report measurement instruments: an illustration from the development of the Brain Tumor Module of the M.D. Anderson Symptom Inventory. <i>Oncology Nursing Forum</i> , 2005 , 32, 669-76	1.7	48
141	Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system. <i>Brain Pathology</i> , 2013 , 23, 584-94	6	45
140	Management of treatment-associated toxicities of anti-angiogenic therapy in patients with brain tumors. <i>Neuro-Oncology</i> , 2012 , 14, 1203-14	1	45
139	Venous thromboembolism (VTE) and glioblastoma. <i>Journal of Neuro-Oncology</i> , 2015 , 124, 87-94	4.8	43
138	Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. <i>Journal of Neuro-Oncology</i> , 2015 , 125, 401-10	4.8	43

137	Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. <i>Lancet Oncology, The</i> , 2012 , 13, e196-204	21.7	43
136	The lomustine crisis: awareness and impact of the 1500% price hike. <i>Neuro-Oncology</i> , 2019 , 21, 1-3	1	43
135	Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. <i>Neuro-Oncology</i> , 2019 , 21, 837-853	1	37
134	Sleep-wake disturbance in patients with brain tumors. <i>Neuro-Oncology</i> , 2017 , 19, 323-335	1	34
133	Complementary and alternative medicine use and quality of life in patients with primary brain tumors. <i>Journal of Pain and Symptom Management</i> , 2006 , 32, 148-54	4.8	34
132	Clinical utility of the MDASI-BT in patients with brain metastases. <i>Journal of Pain and Symptom Management</i> , 2009 , 37, 331-40	4.8	33
131	Personal health records as portal to the electronic medical record. <i>Journal of Neuro-Oncology</i> , 2014 , 117, 1-6	4.8	32
130	Outcomes after surgery and radiotherapy for spinal myxopapillary ependymoma: update of the MD Anderson Cancer Center experience. <i>Neurosurgery</i> , 2014 , 75, 205-14; discussion 213-4	3.2	30
129	Yoga Program for High-Grade Glioma Patients Undergoing Radiotherapy and Their Family Caregivers. <i>Integrative Cancer Therapies</i> , 2018 , 17, 332-336	3	29
128	Reliability and validity of the M. D. Anderson Symptom Inventory-Spine Tumor Module. <i>Journal of Neurosurgery: Spine</i> , 2010 , 12, 421-30	2.8	29
127	The impact of symptom interference using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) on prediction of recurrence in primary brain tumor patients. <i>Cancer</i> , 2011 , 117, 3222-8	6.4	28
126	Clinical course of adult patients with ependymoma: results of the Adult Ependymoma Outcomes Project. <i>Cancer</i> , 2011 , 117, 5133-41	6.4	28
125	Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , 2018 , 20, 897-906	1	26
124	Barriers to accrual and enrollment in brain tumor trials. <i>Neuro-Oncology</i> , 2019 , 21, 1100-1117	1	25
123	Predictors of survival among older adults with ependymoma. <i>Journal of Neuro-Oncology</i> , 2012 , 107, 183-9	2.8	25
122	Envisioning the future in symptom science. <i>Nursing Outlook</i> , 2014 , 62, 346-51	2.7	24
121	Genetic Modulation of Neurocognitive Function in Glioma Patients. <i>Clinical Cancer Research</i> , 2015 , 21, 3340-6	12.9	23
120	Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative. <i>Lancet Oncology, The</i> , 2018 , 19, e173-e180	21.7	23

119	Uncertainty, mood states, and symptom distress in patients with primary brain tumors: analysis of a conceptual model using structural equation modeling. <i>Cancer</i> , 2013 , 119, 2796-806	6.4	21
118	Interventions for the management of fatigue in adults with a primary brain tumour. <i>The Cochrane Library</i> , 2016 , 4, CD011376	5.2	21
117	Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report. <i>Lancet Oncology, The</i> , 2020 , 21, e97-e103	21.7	19
116	Congruence of primary brain tumor patient and caregiver symptom report. <i>Cancer</i> , 2012 , 118, 5026-37	6.4	19
115	Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report. <i>Neuro-Oncology</i> , 2016 , 18 Suppl 2, ii1-ii12	1	18
114	Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD). <i>Neuro-Oncology</i> , 2016 , 18 Suppl 2, ii26-ii36	1	18
113	Patient reported endpoints for measuring clinical benefit in (high grade glioma) primary brain tumor patients. <i>Current Treatment Options in Oncology</i> , 2014 , 15, 519-28	5.4	18
112	Use of complementary and alternative medical therapy by patients with primary brain tumors. <i>Current Neurology and Neuroscience Reports</i> , 2008 , 8, 264-8	6.6	18
111	Imaging techniques in neuro-oncology. <i>Seminars in Oncology Nursing</i> , 2004 , 20, 231-239	3.7	18
110	High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma. <i>Acta Neuropathologica Communications</i> , 2020 , 8, 101	7.3	17
109	Management of steroid-induced hyperglycemia in hospitalized patients with cancer: a review. <i>Oncology Nursing Forum</i> , 2014 , 41, E355-65	1.7	17
108	Validation of the Mishel's uncertainty in illness scale-brain tumor form (MUIS-BT). <i>Journal of Neuro-Oncology</i> , 2012 , 110, 293-300	4.8	17
107	C11orf95-RELA fusion present in a primary supratentorial ependymoma and recurrent sarcoma. <i>Brain Tumor Pathology</i> , 2015 , 32, 105-11	3.2	16
106	Neuroleptic strategies for terminal agitation in patients with cancer and delirium at an acute palliative care unit: a single-centre, double-blind, parallel-group, randomised trial. <i>Lancet Oncology, The</i> , 2020 , 21, 989-998	21.7	16
105	The relationship between corticosteroids and symptoms in patients with primary brain tumors: utility of the Dexamethasone Symptom Questionnaire-Chronic. <i>Neuro-Oncology</i> , 2015 , 17, 1114-20	1	16
104	A case of soft tissue metastasis from glioblastoma and review of the literature. <i>Journal of Neuro-Oncology</i> , 2011 , 103, 167-72	4.8	16
103	Hope and mood changes throughout the primary brain tumor illness trajectory. <i>Neuro-Oncology</i> , 2016 , 18, 119-25	1	15
102	Health-related quality of life and other clinical outcome assessments in brain tumor patients: challenges in the design, conduct and interpretation of clinical trials. <i>Neuro-Oncology Practice</i> , 2015 , 2, 2-5	2.2	15

101	Radiation chronotherapy-clinical impact of treatment time-of-day: a systematic review. <i>Journal of Neuro-Oncology</i> , 2019 , 145, 415-427	4.8	15
100	Pilot randomized, controlled trial of a dyadic yoga program for glioma patients undergoing radiotherapy and their family caregivers. <i>Neuro-Oncology Practice</i> , 2019 , 6, 311-320	2.2	15
99	Wound healing complications in brain tumor patients on Bevacizumab. <i>Journal of Neuro-Oncology</i> , 2015 , 124, 501-6	4.8	14
98	Clinical presentation and outcomes for adult ependymoma patients. <i>Cancer</i> , 2017 , 123, 494-501	6.4	14
97	Net clinical benefit: functional endpoints in brain tumor clinical trials. <i>Current Oncology Reports</i> , 2007 , 9, 60-5	6.3	14
96	Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. <i>Neuro-Oncology</i> , 2021 , 23, 1360-1370	1	14
95	Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases. <i>Future Oncology</i> , 2020 , 16, 899-909	3.6	13
94	Glioblastoma. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2012 , 105, 485-506	3	13
93	Supratentorial gross-totally resected non-anaplastic ependymoma: population based patterns of care and outcomes analysis. <i>Journal of Neuro-Oncology</i> , 2013 , 115, 513-20	4.8	13
92	Neurocognitive function (NCF) outcomes in patients with glioblastoma (GBM) enrolled in RTOG 0825.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2004-2004	2.2	12
91	A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2021 , 23, 1337-1347	1	12
90	Ependymomas arising outside of the central nervous system: A case series and literature review. <i>Journal of Clinical Neuroscience</i> , 2018 , 47, 202-207	2.2	11
89	Seize the moment to learn about epilepsy in people with cancer. <i>Clinical Journal of Oncology Nursing</i> , 2003 , 7, 163-9	1.1	10
88	INNV-33. BARRIERS TO ACCRUAL AND ENROLLMENT IN BRAIN TUMOR TRIALS. <i>Neuro-Oncology</i> , 2019 , 21, vi137-vi137	1	10
87	Clinical and demographic predictors of concussion resolution in adolescents: A retrospective study. <i>Applied Neuropsychology: Child</i> , 2019 , 8, 50-60	1.4	10
86	A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. <i>Neuro-Oncology</i> , 2021 , 23, 468-477	1	10
85	Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT. <i>Journal of Neuro-Oncology</i> , 2019 , 144, 53-63	4.8	9
84	Measuring clinical benefit: use of patient-reported outcomes (PRO) in primary brain tumor clinical trials. <i>Current Oncology Reports</i> , 2013 , 15, 27-32	6.3	9

83	Primary brain tumors and posterior reversible encephalopathy syndrome. <i>Neuro-Oncology Practice</i> , 2014 , 1, 184-190	2.2	9
82	Impact of recall period on primary brain tumor patient's self-report of symptoms. <i>Neuro-Oncology Practice</i> , 2014 , 1, 55-63	2.2	9
81	Head's up on the treatment of malignant glioma patients. <i>Oncology Nursing Forum</i> , 2009 , 36, E232-40	1.7	9
80	Central nervous system toxicity from cancer treatment. <i>Current Oncology Reports</i> , 2004 , 6, 11-9	6.3	9
79	NCOG-01. PRESERVATION OF NEUROCOGNITIVE FUNCTION (NCF) WITH HIPPOCAMPAL AVOIDANCE DURING WHOLE-BRAIN RADIOTHERAPY (WBRT) FOR BRAIN METASTASES: PRELIMINARY RESULTS OF PHASE III TRIAL NRG ONCOLOGY CC001. <i>Neuro-Oncology</i> , 2018 , 20, vi172-vi172	1	9
78	Nursing Guide to Management of Major Symptoms in Patients with Malignant Glioma. <i>Seminars in Oncology Nursing</i> , 2018 , 34, 513-527	3.7	9
77	Symptoms and socio-economic impact of ependymoma on adult patients: results of the Adult Ependymoma Outcomes Project 2. <i>Journal of Neuro-Oncology</i> , 2015 , 121, 341-8	4.8	8
76	A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2020 , 22, 1505-1515	1	8
75	Brain tumor symptoms as antecedents to uncertainty: an integrative review. <i>Journal of Nursing Scholarship</i> , 2012 , 44, 145-55	3.6	8
74	Increased intracranial pressure. <i>Clinical Journal of Oncology Nursing</i> , 2008 , 12, 37-41	1.1	8
73	Seizure risk in brain tumor patients with conversion to generic levetiracetam. <i>Journal of Neuro-Oncology</i> , 2010 , 98, 137-41	4.8	7
72	Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes. <i>Neurosurgery</i> , 2019 , 84, 66-76	3.2	7
71	The impact and incidence of altered body image in patients with head and neck tumors: a systematic review. <i>Neuro-Oncology Practice</i> , 2018 , 5, 204-213	2.2	7
70	Survivorship care planning in neuro-oncology. <i>Neuro-Oncology Practice</i> , 2018 , 5, 3-9	2.2	6
69	Personal health records, symptoms, uncertainty, and mood in brain tumor patients. <i>Neuro-Oncology Practice</i> , 2014 , 1, 64-70	2.2	6
68	Quality improvement in neurology: Neuro-oncology quality measurement set. <i>Neurology</i> , 2018 , 90, 652-658	6.5	5
67	Provider-reported challenges and barriers to referring patients to neuro-oncology clinical trials: a report from the Society for Neuro-Oncology member survey. <i>Neuro-Oncology Practice</i> , 2020 , 7, 38-51	2.2	5
66	Association of genetic variants with fatigue in patients with malignant glioma. <i>Neuro-Oncology Practice</i> , 2018 , 5, 122-128	2.2	5

65	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. <i>Acta Neuropathologica</i> , 2021 , 142, 827-839	14.3	5
64	Impacts of Surgery on Symptom Burden and Quality of Life in Pituitary Tumor Patients in the Subacute Post-operative Period. <i>Frontiers in Oncology</i> , 2019 , 9, 299	5.3	4
63	Significant predictors of patients' uncertainty in primary brain tumors. <i>Journal of Neuro-Oncology</i> , 2015 , 122, 507-15	4.8	4
62	Seizures in people with cancer. <i>Clinical Journal of Oncology Nursing</i> , 2007 , 11, 33-7	1.1	4
61	The treatment of neoplastic meningitis. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 1929-35	4	4
60	The prevalence of altered body image in patients with primary brain tumors: an understudied population. <i>Journal of Neuro-Oncology</i> , 2020 , 147, 397-404	4.8	3
59	Burnout and career satisfaction in neuro-oncology: a survey of the Society for Neuro-Oncology and the European Association of Neuro-Oncology memberships. <i>Neuro-Oncology</i> , 2020 , 22, 838-850	1	3
58	Quality improvement in neurology: Neuro-Oncology Quality Measurement Set. <i>Neuro-Oncology</i> , 2018 , 20, 531-537	1	3
57	The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525. <i>Neuro-Oncology Practice</i> , 2019 , 6, 473-478	2.2	3
56	Caring for an adult with a malignant primary brain tumor. <i>Nursing</i> , 2011 , 41, 28-33; quiz 33-4	0.5	3
55	Chemotherapy of astrocytomas: an overview. <i>Seminars in Oncology Nursing</i> , 1998 , 14, 18-25	3.7	3
54	Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. <i>Clinical Cancer Research</i> , 2021 , 27, 3298-3306	12.9	3
53	Progress in rare central nervous system tumors. <i>Current Opinion in Neurology</i> , 2019 , 32, 895-906	7.1	3
52	Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825). <i>Neuro-Oncology</i> , 2021 , 23, 1125-1138 [†]		3
51	Relationship between symptom burden and health status: analysis of the MDASI-BT and EQ-5D. <i>Neuro-Oncology Practice</i> , 2018 , 5, 56-63	2.2	3
50	See brain cancer as more than just the sum of biology. <i>Nature</i> , 2018 , 561, S45	50.4	3
49	A systematic review of pharmacologic treatment efficacy for depression in older patients with cancer.. <i>Brain, Behavior, & Immunity - Health</i> , 2022 , 21, 100449	5.1	3
48	Reply to M.C. Chamberlain. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1634-5	2.2	2

47	Interventions for the management of fatigue in adults with a primary brain tumour 2014 ,		2
46	Exploring the Cancer Experiences of Young Adults in the Context of Stem Cell Transplantation. <i>Cancer Nursing</i> , 2015 , 38, 260-9	2.6	2
45	NCI-CONNECT: Comprehensive Oncology Network Evaluating Rare CNS Tumors-Histone Mutated Midline Glioma Workshop Proceedings. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdaa007	0.9	2
44	RDNA-04. CIRCADIAN RHYTHMS AND RADIATION CHRONOTHERAPY IN GLIOBLASTOMA CELL LINES AND CENTRAL NERVOUS SYSTEM CELL CONTROLS. <i>Neuro-Oncology</i> , 2019 , 21, vi207-vi207	1	2
43	PATH-28. THE NATURAL HISTORY OF BRAF V600E-MUTATED GLIOBLASTOMAS IN ADULTS. <i>Neuro-Oncology</i> , 2018 , 20, vi164-vi164	1	2
42	Survivorship in Neuro-Oncology. <i>Neuro-Oncology</i> , 2018 , 20, vii4-vii5	1	2
41	RARE-24. OBJECTIVE RESPONSE AND CLINICAL BENEFIT IN RECURRENT EPENDYMOMA IN ADULTS: FINAL REPORT OF CERN 08-02: A PHASE II STUDY OF DOSE-DENSE TEMOZOLOMIDE AND LAPATINIB. <i>Neuro-Oncology</i> , 2018 , 20, vi241-vi241	1	2
40	Patient profiling for treatment toxicity: potential use of clinical and genomic factors. <i>Current Oncology Reports</i> , 2011 , 13, 37-41	6.3	1
39	Glial tumors--new approaches in chemotherapy. <i>Journal of Neuroscience Nursing</i> , 2002 , 34, 326-30	1.5	1
38	High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13.. <i>Acta Neuropathologica</i> , 2022 , 143, 403	14.3	1
37	Identifying symptom recurrences in primary brain tumor patients using the MDASI-BT and qualitative interviews. <i>Journal of Patient-Reported Outcomes</i> , 2019 , 3, 58	2.6	1
36	Venous thromboembolism (VTE) and glioblastoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2033-2033	2.2	1
35	Psychometric validity and reliability of the Danish version of the MD Anderson Symptom Inventory Brain Tumor Module. <i>Neuro-Oncology Practice</i> , 2021 , 8, 137-147	2.2	1
34	Proposed Additions to the NCCN Guidelines for Adult Medulloblastoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 1579-1584	7.3	1
33	Validation study of the Japanese version of MD Anderson Symptom Inventory for Brain Tumor module. <i>Japanese Journal of Clinical Oncology</i> , 2020 , 50, 787-793	2.8	1
32	Use of virtual reality for symptom management in solid-tumor patients with implications for primary brain tumor research: a systematic review. <i>Neuro-Oncology Practice</i> , 2020 , 7, 477-489	2.2	1
31	Letter to the Editor Re: Mohile et al. <i>Neuro-Oncology</i> , 2020 , 22, 1048-1049	1	1
30	Variations in attitudes towards stereotactic biopsy of adult diffuse midline glioma patients: a survey of members of the AANS/CNS Tumor Section. <i>Journal of Neuro-Oncology</i> , 2020 , 149, 161-170	4.8	1

29	Impact of age on the circadian visual system and the sleep-wake cycle in mus musculus. <i>Npj Aging and Mechanisms of Disease</i> , 2021 , 7, 10	5.5	1
28	Association of Circadian Clock Gene Expression with Glioma Tumor Microenvironment and Patient Survival. <i>Cancers</i> , 2021 , 13,	6.6	1
27	SNO 2020 diversity survey: defining demographics, racial biases, career success metrics and a path forward for the field of neuro-oncology. <i>Neuro-Oncology</i> , 2021 , 23, 1845-1858	1	1
26	QOLP-30. CLINICAL PREDICTIVE MODEL FOR THE DEVELOPMENT OF VENOUS THROMBOEMBOLISM IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019 , 21, vi204-vi204	1	1
25	QOLP-36. THE IMPORTANCE OF SLEEP DISTURBANCE IN PRIMARY BRAIN TUMOR (PBT) PATIENTS: CLINICAL CHARACTERISTICS & CO-OCCURRENCE WITH TUMOR-RELATED & PSYCHOLOGICAL SYMPTOMS. <i>Neuro-Oncology</i> , 2019 , 21, vi205-vi206	1	1
24	Clinical trial challenges, design considerations, and outcome measures in rare CNS tumors. <i>Neuro-Oncology</i> , 2021 , 23, S30-S38	1	1
23	Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy. <i>Frontiers in Oncology</i> , 2020 , 10, 601452	5.3	1
22	INNV-41. MY STORI -- A SYMPTOM TRACKING AND REPORTING INSTRUMENT MOBILE APPLICATION FOR CENTRAL NERVOUS SYSTEM CANCER PATIENTS. <i>Neuro-Oncology</i> , 2018 , 20, vi146-vi146	1	1
21	ACTR-13. A BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB VERSUS BEVACIZUMAB PLUS VORINOSTAT IN ADULTS WITH RECURRENT GLIOBLASTOMA FINAL RESULTS. <i>Neuro-Oncology</i> , 2018 , 20, vi13-vi13	1	1
20	PATH-52. UTILIZING NEXT GENERATION SEQUENCING REPORTS IN CLINICAL DECISION MAKING: REPORT FROM THE NATIONAL INSTITUTES OF HEALTH (NIH) NEURO-ONCOLOGY BRANCH (NOB) NATURAL HISTORY STUDY (NHS) PRIMARY BRAIN TUMOR PANEL (PBTP). <i>Neuro-Oncology</i> , 2018 , 20, vi170-vi170	1	1
19	Describing Symptom Burden and Functional Status at the Diagnosis of Leptomeningeal Metastasis. <i>Oncology Nursing Forum</i> , 2018 , 45, 372-379	1.7	1
18	Report of Canonical - Fusion in Glioblastoma. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	1
17	Effects of Cognitive Reserve on Cognition in Individuals With Central Nervous System Disease. <i>Cognitive and Behavioral Neurology</i> , 2021 , 34, 245-258	1.6	1
16	Opportunities and Challenges for the development of 'Core Outcome Sets' in Neuro-Oncology.. <i>Neuro-Oncology</i> , 2022 ,	1	1
15	Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas. <i>Cancers</i> , 2021 , 13,	6.6	1
14	Differences in Circulating Extracellular Vesicle and Soluble Cytokines in Older Versus Younger Breast Cancer Patients With Distinct Symptom Profiles.. <i>Frontiers in Genetics</i> , 2022 , 13, 869044	4.5	1
13	Challenges of imaging interpretation to predict oligodendroglioma grade: a report from the Neuro-Oncology Branch.. <i>CNS Oncology</i> , 2022 , CNS83	4	0
12	Neurocognition and Health-Related Quality of Life Among Patients with Brain Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2022 , 36, 269-282	3.1	0

11	Living with a central nervous system (CNS) tumor: findings on long-term survivorship from the NIH Natural History Study. <i>Neuro-Oncology Practice</i> , 2021 , 8, 460-474	2.2	0
10	Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessment. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab073	0.9	0
9	The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab035	0.9	0
8	Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative. <i>Neuro-Oncology Practice</i> , 2021 , 8, 417-425	2.2	0
7	Accrual and access to neuro-oncology trials in the United States.. <i>Neuro-Oncology Advances</i> , 2022 , 4, vda0048	0.9	0
6	Development of 'Core Outcome Sets' for Meningioma in Clinical Studies (The COSMIC Project): protocol for two systematic literature reviews, eDelphi surveys and online consensus meetings.. <i>BMJ Open</i> , 2022 , 12, e057384	3	0
5	Response to Lai et al., "development of a symptom index for patients with primary brain tumors". <i>Value in Health</i> , 2014 , 17, 752-3	3.3	
4	Cuidar de un adulto con un tumor cerebral primario maligno. <i>Nursing (Ed Española)</i> , 2011 , 29, 8-13		0
3	Associations of meaning of illness with psychosocial, clinical, and immunological characteristics in patients with Leptomeningeal metastasis. <i>Comprehensive Psychoneuroendocrinology</i> , 2021 , 8, 100099	1.1	
2	Glioma patient-reported outcome assessment in clinical care - Authors' reply. <i>Lancet Oncology</i> , 2020 , 21, e231	21.7	
1	Psycho-oncology. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016 , 134, 305-133		